Just one of 20 new cancer drugs examined by the state’s medicines watchdog was considered value for money, according to a new assessment by the body.
Professor Michael Barry, who heads up the National Centre for Pharmacoeoconomics (NCPE), said the assessment of cancer drugs raised “obvious questions” around how we decided to spend limited resources in the health service.
“The question has to be asked - would we be better spending such...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team